Sustained release ranolazine formulations

  • US 6,620,814 B2
  • Filed: 09/27/2002
  • Issued: 09/16/2003
  • Est. Priority Date: 09/10/1998
  • Status: Expired due to Term
First Claim
Patent Images

1. A method for treating a human suffering from a cardiovascular disease selected from arrhythmias, variant and exercise-induced angina, and myocardial infarction by administering a sustained release ranolazine pharmaceutical dosage form having at least 50% by weight ranolazine to the human to maintain ranolazine plasma levels of from about 550 to about 7500 ng base/mL for at least 24 hours.

View all claims

    Thank you for your feedback